Bookmark
Forward
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
Helen L Baron
The Journal of family practice 2017 Oct
Sizes of these terms reflect their relevance to your search.
This article presents the rationale and data for combining a basal insulin with a GLP-1RA, including as fixed-ratio products.
Citation
Helen L Baron.
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
The Journal of family practice.
2017 Oct;66(10 Suppl):S17-S28
Mesh Tags
Diabetes Mellitus, Type 2
Drug Combinations
Drug Therapy, Combination
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents
Insulin, Long-Acting
Insulins
Liraglutide
Male
Middle Aged
Substances
Drug Combinations
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
IDegLira
Insulin, Long-Acting
Insulins
Liraglutide
PMID: 28991933
View Full Text